Biotronik study shows further benefits of superficial femoral artery therapy

Biotronik has announced new clinical data showing the effectiveness of a specific approach to enhancing the effectiveness of superficial femoral artery (SFA) therapy.

Results from various Biotronik studies presented at the 2017 congress of the Cardiovascular and Interventional Radiological Society of Europe have shown that reducing metal burden in SFA therapy could effectively reduce restenosis rates.

Data from the BIOFLEX COF trial established that lower chronic outward force (COF) stents resulted in lower restenosis rates for the first time ever in a dedicated trial of this kind, suggesting a new way forward for planning treatment of SFA disease.

Meanwhile, analysis of the BIOFLEX PEACE registry demonstrated that in a real-world setting, physicians are generally aware of the link between higher COF and elevated restenosis.

Dr Alexander Uhl, vice-president of marketing at Biotronik's vascular intervention division, said: "This exciting data supports our belief that the REACT approach allows the physician to adopt a flexible, evidence-based approach for treating the SFA with minimal vessel burden."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.